UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Ocular side effects of systemically administered chemotherapy

Authors
Catherine Y Liu, MD, PhD
Jasmine H Francis, MD
Jose S Pulido, MD, MS, MPH
David H Abramson, MD, FACS
Section Editors
Paul J Hesketh, MD
Jonathan Trobe, MD
Deputy Editor
Diane MF Savarese, MD

INTRODUCTION

Molecularly targeted agents have emerged as an important component of systemic therapy for a wide range of cancer types. Most of these agents work through mechanisms that are markedly different from conventional cytotoxic chemotherapy, interfering with cellular signaling and angiogenesis pathways that are needed for tumor growth. Many of these agents are associated with distinct adverse effect profiles, several of which affect the eye. Although relatively uncommon, ocular side effects from systemically administered chemotherapy (particularly targeted agents) can be severe, disabling, and irreversible. While some ocular side effects can be managed symptomatically while chemotherapy is continued, others can be vision threatening and warrant immediate discontinuation of the drug.

The ocular side effects of intraarterial chemotherapy administration (including chemotherapy administered into the ophthalmic artery for retinoblastoma) are beyond the scope of this topic review. (See "Retinoblastoma: Treatment and outcome", section on 'Local chemotherapy'.)

OVERVIEW OF THE APPROACH TO THE PATIENT WITH OCULAR SYMPTOMS

When a patient receiving chemotherapy presents with a specific ocular sign or symptom, it is important to delineate whether the complaint is due to the malignancy itself, an associated effect (eg, a paraneoplastic syndrome), or the anticancer treatment.

In general, paraneoplastic visual syndromes are rare; they include cancer-associated retinopathy, melanoma-associated retinopathy, and paraneoplastic optic neuropathy (optic neuritis). (See "Paraneoplastic visual syndromes".)

Differentiating metastasis from drug toxicity — The most common intraocular malignancy is metastatic disease, which most commonly involves the uveal tract. The uvea consists of the iris and ciliary body anteriorly, and the choroid posteriorly (figure 1).

                                                                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2017. | This topic last updated: Aug 17, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. NCI Common Terminology Criteria for Adverse Events Version 4.0 available online at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on March 09, 2017).
  2. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:108.
  3. Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147:206.
  4. Lin P, Fintelmann RE, Khalifa YM, et al. Ocular surface disease secondary to vitamin A deficiency in the developed world: it still exists. Arch Ophthalmol 2011; 129:798.
  5. Samarawickrama C, Chew S, Watson S. Retinoic acid and the ocular surface. Surv Ophthalmol 2015; 60:183.
  6. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52:1922.
  7. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996; 40:343.
  8. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106:336.
  9. Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008; 27:612.
  10. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology 2012; 119:1798.
  11. Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011; 25:355.
  12. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140:509.
  13. Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120:1180.
  14. Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature. Ocul Immunol Inflamm 2016; 24:140.
  15. Waikhom B, Fraunfelder FT, Henner WD. Severe ocular irritation and corneal deposits associated with capecitabine use. N Engl J Med 2000; 343:740.
  16. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 2013; 32:341.
  17. Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol 2011; 12:63.
  18. Bouché O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16:1711.
  19. Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 2007; 16:439.
  20. Vaccaro M, Pollicino A, Barbuzza O, Guarneri B. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 2009; 34:402.
  21. Rodriguez NA, Ascaso FJ. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer. J Clin Oncol 2011; 29:e532.
  22. Specenier P, Koppen C, Vermorken JB. Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol 2007; 18:961.
  23. Dranko S, Kinney C, Ramanathan RK. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6:224.
  24. Tullo AB, Esmaeli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond) 2005; 19:729.
  25. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013; 21:1167.
  26. Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 2009; 28:706.
  27. Chow VW, Jhanji V, Chi SC. Erlotinib-related corneal melting. Ophthalmology 2013; 120:1104.e1.
  28. Lim LT, Blum RA, Cheng CP, Hanifudin A. Bilateral anterior uveitis secondary to erlotinib. Eur J Clin Pharmacol 2010; 66:1277.
  29. Ali K, Kumar I, Usman-Saeed M, Usman Saeed M. Erlotinib-related bilateral anterior uveitis. BMJ Case Rep 2011; 2011.
  30. Roé E, García Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429.
  31. Celik T, Kosker M. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature. Cont Lens Anterior Eye 2015; 38:59.
  32. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007; 23:65.
  33. Jazayeri F, Malhotra R. A case of acquired trichomegaly following treatment with erlotinib. BMJ Case Rep 2009; 2009.
  34. Garibaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007; 23:62.
  35. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol 2006; 1:1040.
  36. Desai RU, Rachakonda LP, Saffra NA. Trichomegaly secondary to erlotinib. Can J Ophthalmol 2009; 44:e65.
  37. Fabbrocini G, Panariello L, Cacciapuoti S, et al. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases. Dermatitis 2012; 23:237.
  38. Munoz J, Hanbali AS. Epidermal growth factor receptor-induced hirsutism and trichomegaly. Mayo Clin Proc 2011; 86:e50.
  39. Papadopoulos R, Chasapi V, Bachariou A. Trichomegaly induced by erlotinib. Orbit 2008; 27:329.
  40. Saif MW, Gnanaraj J. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 2010; 29:62.
  41. Vergou T, Stratigos AJ, Karapanagiotou EM, et al. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 2010; 63:e56.
  42. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007; 23:63.
  43. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13:1011.
  44. Saleh M, Bourcier T, Noel G, et al. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol 2011; 50:477.
  45. Choe CH, McArthur GA, Caro I, et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014; 158:831.
  46. Guedj M, Quéant A, Funck-Brentano E, et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol 2014; 132:1421.
  47. Joshi L, Karydis A, Gemenetzi M, et al. Uveitis as a Result of MAP Kinase Pathway Inhibition. Case Rep Ophthalmol 2013; 4:279.
  48. Lim J, Lomax AJ, McNeil C, Harrisberg B. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. Ocul Immunol Inflamm 2016; :1.
  49. Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect 2015; 5:17.
  50. Yin VT, Wiraszka TA, Tetzlaff M, et al. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. Ophthal Plast Reconstr Surg 2015; 31:e112.
  51. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:773.
  52. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16:1924.
  53. US Prescribing information for trametinib available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1 (Accessed on February 28, 2017).
  54. Niro A, Strippoli S, Alessio G, et al. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series. Am J Ophthalmol 2015; 160:959.
  55. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16:2450.
  56. Martinez-Garcia M, Banerji U, Albanell J, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 2012; 18:4806.
  57. Giuffrè C, Miserocchi E, Modorati G, et al. CENTRAL SEROUS CHORIORETINOPATHYLIKE MIMICKING MULTIFOCAL VITELLIFORM MACULAR DYSTROPHY: AN OCULAR SIDE EFFECT OF MITOGEN/EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITORS. Retin Cases Brief Rep 2016.
  58. Signorelli J, Shah Gandhi A. Cobimetinib. Ann Pharmacother 2017; 51:146.
  59. De La Cruz-Merino L, Di Guardo L, Grob J-J, et al. Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study (abstract). J Clin Oncol 33, 2015 (suppl; abstr 9033). Abstract available online at http://meetinglibrary.asco.org/content/145758-156 (Accessed on March 08, 2017).
  60. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26:2139.
  61. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16:1613.
  62. Leijen S, Middleton MR, Tresca P, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 2012; 18:4794.
  63. Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009; 69:6839.
  64. Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014; 25:1437.
  65. Schoenberger SD, Kim SJ. Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. Case Rep Ophthalmol Med 2013; 2013:673796.
  66. Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 2016; 27:998.
  67. van der Noll R, Leijen S, Neuteboom GH, et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013; 39:664.
  68. van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. Ophthalmology 2015; 122:1907.
  69. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017; 28:1137.
  70. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005.
  71. Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw 2014; 12:1077.
  72. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004; 27:478.
  73. Voskens C, Cavallaro A, Erdmann M, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 2012; 30:e356.
  74. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043.
  75. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 2012; 6:423.
  76. McElnea E, Ní Mhéalóid A, Moran S, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014; 33:424.
  77. McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep 2016; 2016:10.1136/bcr.
  78. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950.
  79. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521.
  80. Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016; 315:1600.
  81. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020.
  82. PAtnaik A, Socinski MA, Gubens MA, et al. Phase I study of pembrolizumab (penbro MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D 9abstract). J Clin Oncol 33, 2015 (suppl; abstr 8011). Abstract available online at http://meetinglibrary.asco.org/content/148437-156 (Accessed on March 02, 2017).
  83. United States prescribing information for avelumab available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118 (Accessed on April 17, 2017).
  84. United States prescribing information for atezolizumab available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee (Accessed on April 17, 2017).
  85. Food and Drug Administration http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf.
  86. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693.
  87. Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014; 19:e5.
  88. Malik SM, Maher VE, Bijwaard KE, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20:2029.
  89. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385.
  90. Chun SG, Iyengar P, Gerber DE, et al. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol 2015; 33:e25.
  91. US prescribing information for crizotinib https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7#S5.5 (Accessed on March 07, 2017).
  92. Besse B, Salgia R, Bolomon B, et al. VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB (abstract 1268P). European Society Medical Oncology 2012.
  93. Muftuoglu O, Uçakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens 2006; 32:228.
  94. Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. Semin Ophthalmol 2012; 27:27.
  95. Pyrhönen S, Ellmén J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56:133.
  96. Bishop J, Murray R, Webster L, et al. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1992; 30:174.
  97. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978; 62:315.
  98. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87:1169.
  99. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996; 14:1018.
  100. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol 2007; 144:126.
  101. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125:493.
  102. McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol 1981; 65:177.
  103. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69:2961.
  104. Yanyali AC, Freund KB, Sorenson JA, et al. Tamoxifen retinopathy in a male patient. Am J Ophthalmol 2001; 131:386.
  105. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond) 1997; 11 ( Pt 3):295.
  106. Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009; 23:109.
  107. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472.
  108. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003; 19:371.
  109. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95:881.
  110. Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond) 2004; 18:760.
  111. Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol 2007; 86:390.
  112. Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 2008; 32:1022.
  113. Christoforidis JB, DeAngelo DJ, D'Amico DJ. Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. Am J Ophthalmol 2003; 135:398.
  114. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012; 32:1375.
  115. DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci 2012; 89:e16.
  116. Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol 2007; 245:1585.
  117. Kusumi E, Arakawa A, Kami M, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004; 18:1138.
  118. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008; 52:331.
  119. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 2005; 31:2427.
  120. Govind Babu K, Attili VS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007; 27:43.
  121. Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 2009; 28:699.
  122. Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012; 30:2008.
  123. Maurizot A, Beressi JP, Manéglier B, et al. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion. Blood Cancer J 2014; 4:e247.
  124. Grob SR, Jakobiec FA, Rashid A, Yoon MK. Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology 2014; 121:1845.
  125. Fraunfelder FW, Yang HK. Association Between Bortezomib Therapy and Eyelid Chalazia. JAMA Ophthalmol 2016; 134:88.
  126. Yun C, Mukhi N, Kremer V, et al. Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy. Hematol Rep 2015; 7:5729.
  127. Veys MC, Delforge M, Mombaerts I. Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis. Clin Lymphoma Myeloma Leuk 2016; 16:e109.
  128. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212.
  129. Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 2013; 31:2123.
  130. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15:1358.
  131. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502.
  132. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109:1188.
  133. Esmaeli B, Valero V. Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? J Clin Oncol 2013; 31:2076.
  134. Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003; 98:504.
  135. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001; 119:1802.
  136. Scaioli V, Caraceni A, Martini C, et al. Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol 2006; 77:79.
  137. Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2. J Clin Oncol 1994; 12:1741.
  138. Capri G, Munzone E, Tarenzi E, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86:1099.
  139. Hofstra LS, de Vries EG, Willemse PH. Ophthalmic toxicity following paclitaxel infusion. Ann Oncol 1997; 8:1053.
  140. Moloney TP, Xu W, Rallah-Baker K, et al. Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol 2014; 14:18.
  141. Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95:233.
  142. Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol 2007; 125:709.
  143. Murphy CG, Walsh JB, Hudis CA, et al. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 2010; 28:e684.
  144. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003; 80:277.
  145. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007; 22:151.
  146. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126:1605.
  147. Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg 2003; 19:216.
  148. Hamersley J, Luce JK, Florentz TR, et al. Excessive lacrimation from fluorouracil treatment. JAMA 1973; 225:747.
  149. Hassan A, Hurwitz JJ, Burkes RL. Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol 1998; 33:14.
  150. Karamitsos A, Kokkas V, Goulas A, et al. Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen. Hippokratia 2013; 17:120.
  151. Caravella LP Jr, Burns JA, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981; 99:284.
  152. Insler MS, Helm CJ. Ankyloblepharon associated with systemic 5-fluorouracil treatment. Ann Ophthalmol 1987; 19:374.
  153. Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand 2000; 78:110.
  154. Seiff SR, Shorr N, Adams T. Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy. Cancer 1985; 56:2148.
  155. Straus DJ, Mausolf FA, Ellerby RA, McCracken JD. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977; 3:15.
  156. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol 1995; 90:1.
  157. Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978; 88:657.
  158. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405.
  159. Shi-Xia X, Xian-Hua T, Hai-Qin X, et al. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51:50.
  160. Horwitz M, Auquier P, Barlogis V, et al. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. Br J Haematol 2015; 168:518.
  161. Holmström G, Borgström B, Calissendorff B. Cataract in children after bone marrow transplantation: relation to conditioning regimen. Acta Ophthalmol Scand 2002; 80:211.
  162. Guthoff T, Tietze B, Meinhardt B, et al. Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica 2010; 224:308.
  163. Mori T, Watanabe M, Kurotori-Sotome T, et al. Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42:197.
  164. Herzig RH, Wolff SN, Lazarus HM, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62:361.
  165. Krema H, Santiago RA, Schuh A, Pavlin CJ. Cytarabine toxicity of the corneal endothelium. Ann Hematol 2013; 92:559.
  166. Dhillon VK, Faraj LA, Elalfy MS, et al. Corneal microcysts. Br J Ophthalmol 2014; 98:138, 147.
  167. Lazarus HM, Hartnett ME, Reed MD, et al. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987; 104:476.
  168. Moberg J, Carlsson M, Holm C, Koranyi G. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside. Acta Ophthalmol 2009; 87:922.
  169. Planer D, Cukierman T, Liebster D, et al. Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside. Am J Hematol 2004; 76:304.
  170. Vogler WR, Winton EF, Heffner LT, et al. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation. Bone Marrow Transplant 1990; 6:405.
  171. Wiznia RA, Rose A, Levy AL. Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia. Retina 1994; 14:253.
  172. Bishop RJ, Ding X, Heller CK 3rd, et al. Rapid vision loss associated with fludarabine administration. Retina 2010; 30:1272.
  173. Spiers AS, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Haematol 1984; 32:130.
  174. Grever MR, Bisaccia E, Scarborough DA, et al. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983; 61:279.
  175. Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9:243.
  176. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7:168.
  177. Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3:1196.
  178. Winick N, Buchanan GR, Murphy SB, et al. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study. Med Pediatr Oncol 1988; 16:327.
  179. Margolis J, Grever MR. Pentostatin (Nipent): a review of potential toxicity and its management. Semin Oncol 2000; 27:9.
  180. Doroshow JH, Locker GY, Gaasterland DE, et al. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 1981; 48:2158.
  181. Balachandran C, McCluskey PJ, Champion GD, Halmagyi GM. Methotrexate-induced optic neuropathy. Clin Exp Ophthalmol 2002; 30:440.
  182. Clare G, Colley S, Kennett R, Elston JS. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol 2005; 25:109.
  183. Johansson BA. Visual field defects during low-dose methotrexate therapy. Doc Ophthalmol 1992; 79:91.
  184. Sbeity ZH, Baydoun L, Schmidt S, Loeffler KU. Visual field changes in methotrexate therapy. Case report and review of the literature. J Med Liban 2006; 54:164.
  185. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004; 43:267.
  186. Schallier D, Decoster L, Fontaine C, De Grève J. Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res 2010; 30:5185.
  187. Kurata T, Tamura K, Okamoto I, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2006; 54:241.
  188. Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011; 6:2083.
  189. Guhl G, Diaz-Ley B, Sanchez-Perez J, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2010; 69:249.
  190. Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol 1989; 108:709.
  191. Wickremasinghe S, Dansingani KK, Tranos P, et al. Ocular presentations of breast cancer. Acta Ophthalmol Scand 2007; 85:133.
  192. Cardoso F, Ferreira Filho AF, Crown J, et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 2001; 21:789.
  193. Wang WS, Tzeng CH, Chiou TJ, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1997; 27:154.
  194. Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011; 96:621.
  195. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25:292.
  196. Ko MW, Tamhankar MA, Volpe NJ, et al. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci 2008; 273:144.
  197. Al-Muammar AM, Al-Mudhaiyan TM, Al Otaibi M, et al. Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int Ophthalmol 2010; 30:611.
  198. Lim JH, Lee YN, Kim YS, et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol 2011; 17:61.
  199. Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 2003; 10:467.
  200. Touitou V, Bodaghi B, Cassoux N, et al. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 2005; 140:949.
  201. Foon KA, Roth MS, Bunn PA Jr. Interferon therapy of non-Hodgkin's lymphoma. Cancer 1987; 59:601.
  202. Hernández-Núñez A, Fernández-Herrera J, Buceta LR, García-Díez A. Trichomegaly following treatment with interferon alpha-2b. Lancet 2002; 359:1107.
  203. Howaizi M. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20:1945.
  204. Ozdoğan M, Gür G, Kadayifcilar S, et al. An unusual adverse effect of interferon: hypertrichosis of the eyelashes. J Interferon Cytokine Res 2000; 20:633.
  205. Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.
  206. Berglund EF, Burton GV, Mills GM, Nichols GM. Hypertrichosis of the eyelashes associated with interferon-alpha therapy for chronic granulocytic leukemia. South Med J 1990; 83:363.
  207. Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond) 1999; 13 ( Pt 2):241.
  208. Esmaeli B, Koller C, Papadopoulos N, Romaguera J. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001; 108:858.
  209. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111:350.
  210. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001; 131:782.
  211. Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopathy. Br J Ophthalmol 2003; 87:247.
  212. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88:1518.
  213. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82:323.
  214. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85:1171.
  215. Lim JW, Shin MC. Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica 2010; 224:224.
  216. Malik NN, Sheth HG, Ackerman N, et al. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol 2008; 92:256.
  217. Zegans ME, Anninger W, Chapman C, Gordon SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002; 13:423.
  218. Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009; 53:598.
  219. Nicolò M, Artioli S, La Mattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005; 15:811.
  220. Kiratli H, Irkeç M. Presumed interferon-associated bilateral macular arterial branch obstruction. Eye (Lond) 2000; 14:920.
  221. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007; 48:368.
  222. Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994; 21:474.
  223. Norcia F, Di Maria A, Prandini F, Redaelli C. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999; 213:339.
  224. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995; 113:1041.
  225. Kiuchi K, Kitagawa C, Miyashiro M. [Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon]. Nippon Ganka Gakkai Zasshi 2009; 113:16.
  226. Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet 1999; 353:1326.
  227. Shahidullah AB, Cerulli MA, Berman DH. Interferon may cause retinopathy during hepatitis therapy. Am J Gastroenterol 1995; 90:1543.
  228. Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13:3137.
  229. Wei YH, Wang IH, Woung LC, Jou JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm 2009; 17:191.
  230. Chan JW. Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C. Eye (Lond) 2007; 21:877.
  231. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27:1421.
  232. Dulz S, Asselborn NH, Dieckmann KP, et al. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. J Cancer Res Clin Oncol 2017; 143:1319.
  233. Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol 2000; 130:367.
  234. Feun LG, Wallace S, Stewart DJ, et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984; 54:794.
  235. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997; 28:310.
  236. Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992; 113:435.
  237. Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 1993; 84:237.
  238. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92:402.
  239. Lewis P, Waqar S, Yiannakis D, Raman V. Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma. Case Rep Oncol 2014; 7:29.
  240. Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Ann Oncol 1993; 4:337.
  241. Painhas T, Amorim M, Soares R, et al. Idiopathic intracranial hypertension and oxaliplatin: a causal association? Cutan Ocul Toxicol 2015; 34:237.
  242. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982; 100:1766.
  243. Khawly JA, Rubin P, Petros W, et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996; 103:87.
  244. Johnson DW, Cagnoni PJ, Schossau TM, et al. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant 1999; 24:785.
  245. Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 1972; 56:999.
  246. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 1966; 41:581.
  247. Abu el-Asrar AM, al-Momen AK, Harakati MS. Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment. Doc Ophthalmol 1993; 84:373.
  248. Guirgis MF, Lueder GT. Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. J AAPOS 2003; 7:432.
  249. Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 1989; 25:805.
  250. Marmor MF, Jain A, Moshfeghi D. Total rod ERG suppression with high dose compassionate Fenretinide usage. Doc Ophthalmol 2008; 117:257.
  251. Modiano MR, Dalton WS, Lippman SM, et al. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs 1990; 8:317.
  252. Brown RD, Grattan CE. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989; 73:286.
  253. Denman S, Weleber R, Hanifin JM, et al. Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne. J Am Acad Dermatol 1986; 14:692.
  254. Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986; 104:831.
  255. Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol 1967; 78:709.
  256. Sarkar S, Deb AR, Saha K, Das CS. Simultaneous isolated bilateral facial palsy: a rare vincristine-associated toxicity. Indian J Med Sci 2009; 63:355.
  257. Toker E, Yenice O, Oğüt MS. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 2004; 8:69.
  258. Norton SW, Stockman JA 3rd. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus 1979; 16:190.
  259. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976; 81:146.
Topic Outline

GRAPHICS